Metabolic Imaging in Prostate Cancer: Where We Are
Open Access
- 9 November 2016
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 6, 225
Abstract
In recent years, the development of diagnostic methods based on metabolic imaging has been aimed at improving diagnosis of prostate cancer (PCa) and perhaps at improving therapy. Molecular imaging methods can detect specific biological processes that are different when detected within cancer cells relative to those taking place in surrounding normal tissues. Many methods are sensitive to tissue metabolism; among them, positron emission tomography (PET) and magnetic resonance spectroscopic imaging (MRSI) are widely used in clinical practice and clinical research. There is a rich literature that establishes the role of these metabolic imaging techniques as valid tools for the diagnosis, staging, and monitoring of PCa. Until recently, European guidelines for PCa detection still considered both MRSI/MRI and PET/CT to be under evaluation, even though they had demonstrated their value in the staging of high risk PCa, and in the restaging of patients presenting elevated prostatic-specific antigen levels following radical treatment of PCa, respectively. Very recently, advanced methods for metabolic imaging have been proposed in the literature: multiparametric MRI (mpMRI), hyperpolarized MRSI, PET/CT with the use of new tracers and finally PET/MRI. Their detection capabilities are currently under evaluation, as is the feasibility of using such techniques in clinical studies.Keywords
This publication has 52 references indexed in Scilit:
- 11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient seriesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillanceAbdominal Radiology, 2014
- Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer.2012
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Prostate Cancer: Sextant Localization at MR Imaging and MR Spectroscopic Imaging before Prostatectomy—Results of ACRIN Prospective Multi-institutional Clinicopathologic StudyRadiology, 2009
- A definition of molecular imaging.2007
- Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.2007
- Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopyMagnetic Resonance in Medicine, 2006
- Prostate Depiction at Endorectal MR Spectroscopic Imaging: Investigation of a Standardized Evaluation SystemRadiology, 2004
- Terminal oxidation and the effects of zinc in prostate versus liver mitochondriaMitochondrion, 2004